NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB 29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10

29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10

[Epub ahead of print] PubMed PMID: 24365180

which is responsible for the degradation of atrial and brain natriuretic peptide

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

It increases H3K4 methylation selectively at genomic regions bound by LSD1

NVP-BGT226 - PI3K/mTOR Dual Inhibitor. CAS# 1245537-68-1 ral-LSB 29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10NVP BGT226, CAS No. 1245537 68 1, is a novel dual PI3K mTOR inhibitor with an IC50 ~1 nM. In cellular assays it could produce nearly complete inhibition of PI3K signaling at low nanomolar (<50 nM) concentrations. Flow cytometric analysis revealed an accumulation of cells in the G0G1 phase with a concomitant loss in the S phase. TUNEL assay and the analysis of Caspase 3 7 and PARP indicated that BGT226 induced cancer cell death through an apoptosis